Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03684785 |
|
Recruitment Status :
Terminated
(The study was canceled for administrative reasons.)
First Posted : September 26, 2018
Last Update Posted : April 7, 2022
|
Sponsor:
Exicure, Inc.
Information provided by (Responsible Party):
Exicure, Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Terminated |
|---|---|
| Actual Primary Completion Date : | March 30, 2022 |
| Actual Study Completion Date : | March 30, 2022 |